KalshiClosedCheck availabilityKYC requiredVerified resolution dataWell calibratedThis market is closed and awaiting confirmed resolution.
Awaiting verified resolution
CoinRithm is waiting for provider-confirmed settlement before treating this market as resolved.
Current implied probability
before April 2027 69%Leader of 6 outcomes
before April 2027 69%Market quality
34 / 100
Low quality24h Volume
—
Open interest
$21.9K
Medium open interestMarket data
Updated 9 minutes ago
Mar 24, 26, 2:00 PM UTCSep 1, 26, 2:00 PM UTC
Trends
before April 202769%
before 202751%
before December27%
before November6%
before OctoberLost
before SeptemberLost
Related Markets
Related questions for context, not a comparison of equivalent contracts.
How many human screwworm cases will be reported in the United States in 2026?
KalshiHow many tuberculosis cases will be reported in the United States in 2026?
KalshiWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill WHO classify the current hantavirus outbreak as a Public Health Emergency of International Concern by end of 2026?
Manifold MarketsWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWhich countries will have an Ebola case in 2026?
PolymarketRules
This outcome's exact rule is not available.
Rules for each outcome
- before April 2027
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
- before 2027
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- before December
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- before November
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- before October
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- before September
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.